Search

iOnctura PI3K-δ Inhibitor Patent Granted

The USPTO granted Patent US12605389B2 to iOnctura SA covering a PI3K-δ inhibitor compound and its use in methods of treating diseases where PI3Kδ pathway signaling is pathologically implicated. The patent encompasses the compound and its salts for treating cancer and inflammatory or autoimmune diseases, with 14 claims. The patent application was filed on March 29, 2022.